通过增强NSCLC中的B细胞透,CSDE1的减少抑制了瘤的进展
Wanting Li1,2,3,4,5, Shijian Xiang6,7, Ke Liu1,2,3
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Cell death & disease
|December 6, 2025
概括
通过抑制瘤透B淋巴细胞 (TIL-Bs),CSDE1促进肺癌. 删除CSDE1会增加TIL-Bs,抑制瘤生长并增强抗癌免疫力,突出显示B细胞作为治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 虽然T细胞主导着免疫疗法研究,但瘤透性B淋巴细胞 (TIL-Bs) 越来越多地被认为具有治疗潜力.
- CSDE1与癌症和免疫反应有关,但其在肺癌进展和瘤免疫微环境中的具体作用尚不清楚.
研究的目的:
- 研究CSDE1在肺癌进展中的作用.
- 确定CSDE1对瘤免疫微环境的影响,特别是TIL-B种群.
- 探索CSDE1作为肺癌免疫治疗中的潜在治疗标.
主要方法:
- 在体内研究中使用了具有Csde1淘汰 (KO) 的瘤携带小鼠模型.
- 使用单细胞RNA测序 (scRNA-seq) 来分析免疫细胞群和基因表达.
- 通过流式细胞计和免疫光检测证实了这些发现.
- 在Csde1 KO小鼠中通过减少B细胞的作用进行了研究.
主要成果:
- 在体内,CSDE1促进肺癌的进展,但在体内却没有.
- Csde1 缺失显著抑制了小鼠的瘤生长.
- Csde1 KO重塑了瘤免疫微环境,显著增加了TIL-B水平.
- 在Csde1 KO小鼠中,B细胞介导的幽默免疫力得到增强.
- B细胞枯竭逆转了在Csde1 KO小鼠中观察到的瘤生长抑制.
结论:
- 通过负调节TIL-Bs和瘤免疫微环境,CSDE1促进肺癌的进展.
- 向CSDE1可能是一个新的免疫疗法策略,利用B细胞的抗瘤作用.
- 这项研究强调了B细胞在抗癌免疫和治疗反应中的关键作用.
相关概念视频
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
02:40Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
01:01Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K